<DOC>
	<DOC>NCT02028871</DOC>
	<brief_summary>This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.</brief_summary>
	<brief_title>Intranasal Insulin for Weight Management During Smoking Cessation</brief_title>
	<detailed_description />
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>smokers (&gt;10 cig/day) for the past 1 year normosmic olfactory function previous/current use of insulin current Diagnostic and Statistical ManualIVRevised (DSMIVR) Axis I disorder current pregnancy (or lactation) lifetime history of endocrine disease excessive alcohol use (&gt;25 standard units of alcohol/week) current use of illicit drugs current use of a smoking cessation aid (NRT, Chantix or Wellbutrin), or a psychotropic agent local infections, inflammation, structural abnormalities, or other nasal pathology current use of any medications administered intranasally, including intranasal steroids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>